Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSF +15.85%83 Future 3-5Y EPS without NRI Growth Rate is 7.09 as of Aug. 23, 2026. GuruFocus rates EBOSF with a GF Score™ of 83/100 and a GF Value™ of $40.93. The stock has 5 warning signs investors should review. Among 30 Medical Distribution companies, Ebos Group ranks worse than 76.67% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Ebos Group's Future 3-5Y EPS without NRI Growth Rate is 7.09.
Ebos Group (OTCPK:EBOSF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Ebos Group Future 3-5Y EPS without NRI Growth Rate Related Terms
EBOSF vs MCK, COR, CAH: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Distribution subindustry, Ebos Group's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Future 3-5Y EPS without NRI Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ebos Group's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 7.09 mean?
Ebos Group (EBOSF) has a Future 3-5Y EPS without NRI Growth Rate of 7.09 as of Aug. 23, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #23 out of 30 companies in the Medical Distribution industry, placing it in the top 76.7%.
Is Ebos Group's Future 3-5Y EPS without NRI Growth Rate too high?
Ebos Group's current Future 3-5Y EPS without NRI Growth Rate is 7.09. The Medical Distribution industry median Future 3-5Y EPS without NRI Growth Rate is 11.68. Ebos Group's value of 7.09 is 39.3% below this industry median. Based on the distribution chart, Ebos Group ranks #23 out of 30 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ebos Group has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Future 3-5Y EPS without NRI Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #23 out of 30 companies for Future 3-5Y EPS without NRI Growth Rate. This places Ebos Group in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 11.68. Ebos Group's value of 7.09 is 39.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Distribution company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Distribution companies is 11.68, based on 30 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Future 3-5Y EPS without NRI Growth Rate of 7.09 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Ebos Group and its competitors. For the Medical Distribution industry, the median Future 3-5Y EPS without NRI Growth Rate is 11.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Future 3-5Y EPS without NRI Growth Rate is 7.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current Future 3-5Y EPS without NRI Growth Rate of 7.09. The stock's GF Value™ is $40.93, compared to a current price of $23.75 — trading 42% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 7.09 and 39.3% below the Medical Distribution industry median of 11.68. Ebos Group's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Ebos Group (EBOSF), the current Future 3-5Y EPS without NRI Growth Rate is 7.09 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 42% below its estimated GF Value™ of $40.93.
Key valuation signals for EBOSF:
Future 3-5Y EPS without NRI Growth Rate: 7.09
GF Value™: $40.93 vs. price of $23.75 (42% below fair value)
Industry Position: 39.3% below the Medical Distribution median (#23 of 30)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
83GF Score
Get the complete analysis for EBOSF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
